Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8071 to 8085 of 9079 results

  1. Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]

    In development Reference number: GID-TA11663 Expected publication date: TBC

  2. Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]

    In development Reference number: GID-TA11808 Expected publication date: TBC

  3. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

  4. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

  5. Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update)

    Discontinued Reference number: GID-NG10300

  6. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    Discontinued Reference number: GID-TA10596

  7. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    Discontinued Reference number: GID-TA10597

  8. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

  9. Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]

    In development Reference number: GID-TA11709 Expected publication date: TBC

  10. Lung transplantation with ex-vivo perfusion

    Discontinued Reference number: GID-IP1046

  11. Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]

    In development Reference number: GID-TA11751 Expected publication date: TBC

  12. Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

    In development Reference number: GID-TA10667 Expected publication date: TBC

  13. Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]

    Discontinued Reference number: GID-TA11264

  14. Evobrutinib for treating relapsing multiple sclerosis [ID6313]

    Discontinued Reference number: GID-TA11357